Market Place
Sourcing Support
Agendia`s FLEX Study Enrolls 17,000+ Breast Cancer Patients
12 Sep 2024 //
BUSINESSWIRE
Agendia Achieves CE-IVDR Certification For MammaPrint® And BluePrint® Assays
16 Aug 2024 //
BUSINESSWIRE
Agendia Publishes MammaPrint® Utility In Endocrine Therapy Prediction
30 Jul 2024 //
BUSINESSWIRE
Agendia Assesses Immune State In Early Breast Cancer At ASCO 2024
31 May 2024 //
BUSINESSWIRE
Agendia Presents 3-Year Chemo Outcome Data In Early Breast Cancer At ASCO
31 May 2024 //
BUSINESSWIRE
Agendia Breast Cancer Suite: Asco 2024 Data To Advance Care
24 May 2024 //
BUSINESSWIRE
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature
20 Mar 2024 //
BUSINESSWIRE
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study
16 Nov 2022 //
BUSINESSWIRE
Agendia Presents Data from FLEX Real World Evidence Trial in 7 Posters at ASCO
05 Jun 2022 //
BUSINESSWIRE
Agendia`s MammaPrint, BluePrint Capture Full Spectrum of Early Breast Cancer
07 Feb 2022 //
BUSINESSWIRE
Agendia to Provide First Digital MammaPrint Capability to Brazil
12 Jan 2022 //
BUSINESSWIRE
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
10 Jan 2022 //
BUSINESSWIRE
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors
06 Jan 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.